

## Title:

# “New Target for Treatment of Immune Inflammatory Diseases – From Novel Biology to First-in-Human”.

## ABSTRACT TEMPLATE: CHECKLIST AND INSTRUCTIONS

Please complete the ABSTRACT TEMPLATE online, for Biomed 2025 Company Presentations

All items marked with an \* are mandatory to complete

The maximum number of words for this abstract is 400

Please be sure to complete the following:

Company name: ImmuneWalk Therapeutics

Website: <https://www.immunewalk.com>

CEO name: Prof. Dror Harats

CATEGORY: Biotech/Pharma

- Immunology and Inflammation Reclaim top Priorities in BioPharma: Driver and Opportunities

o Executive Summary / Investment Rational Briefly describe the company's technology or therapeutic focus; the market opportunity, progress made to date, key partnerships or joint ventures, investment to date; and management strengths.

**New Biology Translated to Innovative Therapy:** ImmuneWalk Therapeutics is clinical-stage I&I company with first-in-class mAb for highly prevalent and rare inflammatory indications, addressing a multi-billion \$ market. Over \$20M have been invested in the program to date.

o Core Technology What is the technology, its uniqueness, and its value proposition?

There is no treatment specifically targeting monocytes & neutrophils, key innate immune cells controlling the inflammatory response. We developed a differentiated technology, based on new biology – targeting a novel adhesion checkpoint that blocks the ability of these cells to reach inflamed tissues.

o Product Profile/Pipeline Briefly describe the company's product/pipeline, status, and market potential. Discuss milestones, potential collaborations, and partnerships.

Lead candidate IW-601 is a proprietary mAb engineered to specifically prevent monocytes & neutrophils from exiting the blood stream and traveling to inflammatory sites. With clear disease-modifying activity in models of Multiple Sclerosis, Rheumatoid Arthritis, Inflammatory Bowel Disease and NASH, and PoC from patients' cells, IW-601 is currently studied in Ph1 trial.

o Business Strategy Briefly describe how the company will apply its core technology, generate short-term and long-term revenues.

IW-601 has potential to be broadly applicable across prevalent & rare inflammatory indications. Our current focus is on human proof-of-concept and safety. Our Ph1 SAD stage was completed successfully. Ph1 MAD data in 3Q25 & Ph2a data in 2026 expected to drive significant upside. Potential for BLA filing in 2H28/2029

o What's Next? R&D, Preclinical / Clinicals, Organizational Plans, Financial Plans

Beyond advancing IW-601 through clinical trials for I&I indications, our program has potential in oncology, as MOSPD2 is also implicated in cancer metastasis. The company is raising money to advance its clinical program.